Research Calls
- Upgrades:
- Anheuser-Busch InBev (BUD) upgraded to Buy from Neutral at Citigroup
- Antero Resources (AR) upgraded to Buy from Hold at Truist; tgt raised to $50
- Excelerate Energy (EE) upgraded to Overweight from Equal Weight at Wells Fargo; tgt $29
- Universal Music Group N.V. (UMGNF) upgraded to Conviction Buy from Buy at Goldman
- Downgrades:
- Aegon N.V. (AEG) downgraded to Underperform from Neutral at Exane BNP Paribas
- Aveanna (AVAH) downgraded to Hold from Buy at Truist
- Burberry plc (BURBY) downgraded to Neutral from Outperform at Exane BNP Paribas
- HP Inc. (HPQ) downgraded to In-line from Outperform at Evercore ISI; tgt lowered to $36
- NovoCure (NVCR) downgraded to Underperform from In-line at Evercore ISI
- PerkinElmer (PKI) downgraded to In-line from Outperform at Evercore ISI; tgt $150
- Sony (SONY) downgraded to Neutral from Buy at Citigroup
- Talaris Therapeutics (TALS) downgraded to Equal-Weight from Overweight at Morgan Stanley; tgt lowered to $8
- Others:
- NetEase (NTES) initiated with an Outperform at Macquarie; tgt $129
- Shopify (SHOP) initiated with a Mkt Perform at JMP Securities
- Symbotic (SYM) initiated with a Buy at Needham; tgt $18
- Symbotic (SYM) initiated with an Outperform at Raymond James; tgt $18
- Teradyne (TER) initiated with a Neutral at JP Morgan; tgt $120
Gapping down
Select Index ETFs showing weakness:
- IWM -0.8%, QQQ -0.8%, SPY -0.6%, DIA -0.5%
News:
- NIU -6.4% (reports Q2 sales volume declined 17.4% yr/yr)
- CVM -6.1% (files for $150 mln mixed securities shelf offering)
- SRRK -3.2% (to Present Phase 3 SAPPHIRE Trial Design at the 17th International Congress on Neuromuscular Disease)
- PHG -2.8% (completes cancellation of 8.8 million shares)
- DWAC -2% (SEC filing that it has been subpoenaed in federal criminal probe)
- CME -2% (reports Q2 and June 2022 market statistics)
- ATAI -1.9% (files for $300 mln mixed securities shelf offering)
- CHPT -1.6% (files for $1 bln mixed securities shelf offering)
- TSLA -1% (reports Q2 production of 258,580 vehicles)
Analyst comments:
- AEG -6.5% (downgraded to Underperform from Neutral at Exane BNP Paribas)
![]()
Gapping up
News:
- COWN +14.4% (Toronto-Dominion Bank (TD) is considering possible bid for COWN, according to Bloomberg)
- DYN +11.1% (FDA lifts clinical hold, clears IND application to initiate clinical trial of DYNE-251)
- OCFT +10.8% (successfully lists on the Main Board of the Stock Exchange of Hong Kong)
- REI +6.4% (acquires Stronghold's Permian Basin assets)
- DRIO +5.9% (files for 226,586 share common stock offering by selling shareholder related to warrants)
- TRP +4.5% (agreed with Mexico to build a $5 bln gas pipeline in Veracruz, according to Reuters)
- VET +3.6% (receives TSX approval for normal course issuer bid)
- ASTS +3.5% (sells majority stake in NanoAvionics)
- FULC +3.3% (enrolls first patient in pivotal global Phase 3 clinical trial of Losmapimod)
- QD +2.4% (completes the optional repurchase of 1.00% Convertible Senior Notes due 2026)
- ISEE +1.6% (IVERIC bio and DelSiTech Ltd announce an exclusive global license agreement for new formulations of Zimura; ISEE to make upfront payment of €1.25 mln)
- OXY +1.2% (10% owner Berkshire Hathaway (Warren Buffett) bought 9,887,040 shares worth ~$582.4mln)
Analyst comments:
- AR +2.2% (upgraded to Buy from Hold at Truist)
Early premarket gappers
- Gapping up:
- COWN +12.2%, OCFT +10.8%, ASTS +7.7%, TUP +6.3%, DRIO +5.9%, VET +4.2%, QD +3.2%, CVM +2.4%, OXY +1.3%, HTA +1.1%, SGEN +1%, ICPT +0.9%, TRP +0.7%, ABC +0.6%
- Gapping down:
- NIU -6.2%, ATAI -6%, PHG -3.3%, SRRK -3.2%, BGXX -2.7%, DWAC -1.7%, CHPT -0.6%, ABOS -0.6%, IWM -0.6%, QQQ -0.6%, IPSC -0.5%, NEGG -0.5%, VERV -0.5%, SPY -0.5%
Find below an update on Porsche AG’s potential IPO
1/ Conclusion
We do not believe a long PAH3 holding discount is attractive.
Indeed, we calculate the PAH3’s holding discount post IPO to be around -25.3% and do not expect it to be tighter (holding’s risk profile increased by the €6.6bn net debt post Porsche AG’s IPO)
The key unknown remains the discount that will be applied by the market on Porsche AG’s unlisted Ord shares versus Pref (we use 20%)
However, we still believe there is value in a long PAH3’s position and hence suggest a Long PAH3/Short SXAP position
Even more so since such a position would have only returned a positive 1.8% IRR since Feb 18th but such IRR was as high as 18% early April
2/ Recent disclosures
PAH3 and VOW heads of agreement terms as of May 05 at Q1 2022 results:
- Porsche AG capital to be divided in 50% Pref shares and 50% Ord shares
- 25% of Porsche AG’s Pref Shares to be placed during IPO
- PAH3 to acquire 25% + 1 share of Porsche AG Ord shares at a 7.5% premium to Porsche AG’s Pref share’s placement price
- 49% of the total proceeds (IPO of Pref shares + sale of Ord shares) to be distributed to shareholders
- A progress update will be made in Late summer 2022
We are assuming that Porsche AG’s Pref shares will have no vote
3/ Expected structure of Porsche AG’s capital
4/ PAH3’s control of Porsche AG
We are assuming at this stage that Porsche AG is IPOed debt free as we have no details
We are now assuming that PAH3 would finance the acquisition of its 25% + 1 share of Porsche AG Ord shares 100% in debt
PAH3 controls 31.4% of VOW’s capital and 53.3% of VOW’s voting rights
PAH3 would control 65% of Porsche AG’s voting rights
5/ Detailed calculations
Find below our calculations on the potential Porsche AG’s IPO and impact for PAH3
We use a 55% discount to RACE IM’s multiple hence an implied €78.6bn equity value for Porsche AG
PAH3 would need to raise €7.4bn post special dividend to finance the acquisition of its 25% + 1 share of Porsche AG Ord shares (12.5% of Porsche AG’s capital)
6/ PAH3’s holding discount
PAH3 current discount to NAV is -32.6% but was as tight as -26% early April
Implied PAH3 holding discount post IPO:
- If we were not to consider any discount for PAH3’s position in Porsche AG’s Ord versus the Pref, the implied discount post IPO would be -30.5%
- When considering a 20% discount as per the SOP post IPO below, PAH3 holding discount would be -25.3%
PAH3 has currently no debt and would end up post IPO with a net debt of €6.6bn. This is acceptable but would raise the holding’s risk profile
Find below, PAH3’s current discount to NAV:
We make the following assumptions for our PAH3 SOP post Porsche AG’s IPO:
- An equity value of €79bn for Porsche AG
- We apply a 20% discount to PAH3’s position in Porsche AG’s Ord versus Pref’s IPO price (unlisted)
- PAH3 would pay €10.6bn for the stake but receive €3.1bn in special dividend which means they only have to finance €7.4bn
- We use VOW ex special dividend price to calculate the value of PAH3’s VOW post IPO
David
